FranΓ§aisπ See the interactive version (live chart) β
For Cigna, we replayed every analyst price target of the past 12 months and measured the real outcome: 35% were profitable, average return +11% (244 calls). At 3 months: +3% average return (46% profitable). The higher the %, the more often analysts were right on this stock.
Their past track record on this stock (targets replayed against real prices) β not a forecast of what will happen.
| Analyst / broker | Calls i | % profitable i | Avg return i |
|---|---|---|---|
| Morgan Stanley | 25 | 24% | +10% |
| Deutsche Bank | 23 | 61% | +24% |
| Raymond James | 18 | 33% | +16% |
| Credit Suisse | 13 | 38% | +18% |
| Cantor Fitzgerald | 13 | 0% | -9% |
Is Cigna overvalued, and is it a good time to buy Cigna right now? If you're wondering, here's a recap to make up your own mind: Cigna's valuation vs its sector median, to weigh alongside analyst reliability (above) and past performance. Educational information, not buy advice.
The P/E (price Γ· earnings per share) = how many years of earnings you pay for the stock. The higher it is, the more growth the market expects β but the pricier the stock, so more vulnerable if growth disappoints. The forward P/E uses next year's expected earnings: lower than the current P/E = rising expected earnings. We compare it to the sector median to see whether the stock is expensive relative to its peers.
| Metric | Cigna | Sector median (Health Care) |
|---|---|---|
| P/E | 11.5 | 29.4 |
| Forward P/E | 8.3 | 17.1 |
| Net margin | 2% | 12% |
π Cigna trades below its sector median (11.5 vs 29.4) β potentially undervalued, or lower expected growth.
π P/E, PEG, marginβ¦: see the glossary
π΅ Dividend : Cigna pays about $6.14/share/yr β 2.22% yield. what is this?
The analyst consensus on Cigna (CI) is "Buy" (28 bullish, 0 bearish calls over 12 months). This is not advice: historically, 35% of their targets on this stock turned out profitable over 1 year.
The median 12-month price target is $340 (+22% vs $278), ranging from $302 to $400 (13 analysts).
Over 1 year, 35% of analyst targets on Cigna were profitable, for an average return of +11% (across 244 timestamped calls). This is JPI Invest's accuracy metric.
Analysts target a median of $340 within 12 months, i.e. +22% vs the current price. The most bullish targets $400, the most cautious $302.
Note: analyst targets are 12-month (median $340, +22%), NOT 2030. No reliable 5-10 year price forecast exists (Β« 2030 prediction Β» models are speculative). The most useful inputs: the 12-month median above, these analysts' historical accuracy (35%), and the stock's past trajectory.
Its P/E is 11.5, forward P/E 8.3. A forward P/E lower than the current P/E means earnings are expected to grow.
π See the full interactive analysis of Cigna β
JPI Invest aggregates analyst recommendations across the entire S&P 500 (plus the S&P MidCap 400), replays them against real prices and measures who predicts best β on results, not reputation. Instead of taking a price target at face value, you see each analyst's track record on each stock.
Explore JPI Invest for free β How it works: the method β
β οΈ Educational information, not investment advice. Analyst price targets are 12-month and can be wrong. Data via Yahoo Finance, recomputed by JPI Invest.